Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain
- 15 October 2013
- journal article
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 27 (1) , 124-133
Abstract
Summary: Resistance to the BRAF inhibitor vemurafenib poses a significant problem for the treatment of BRAFV600E‐positive melanomas. It is therefore critical to prospectively identify all vemurafenib resistance mechanisms prior to their emergence in the clinic. The vemurafenib resistance mechanisms described to date do not result from secondary mutations within BRAFV600E. To search for possible mutations within BRAFV600E that can confer drug resistance, we developed a systematic experimental approach involving targeted saturation mutagenesis, selection of drug‐resistant variants, and deep sequencing. We identified a single nucleotide substitution (T1514A, encoding L505H) that greatly increased drug resistance in cultured cells and mouse xenografts. The kinase activity of BRAFV600E/L505H was higher than that of BRAFV600E, resulting in cross‐resistance to a MEK inhibitor. However, BRAFV600E/L505H was less resistant to several other BRAF inhibitors whose binding sites were further from L505 than that of PLX4720. Our results identify a novel vemurafenib‐resistant mutant and provide insights into the treatment for melanomas bearing this mutation.Keywords
This publication has 23 references indexed in Scilit:
- V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathwayProceedings of the National Academy of Sciences, 2009
- Potent and selective pyrazole-based inhibitors of B-Raf kinaseBioorganic & Medicinal Chemistry Letters, 2008
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- Harnessing homologous recombination in vitro to generate recombinant DNA via SLICNature Methods, 2007
- New insight into BRAF mutations in cancerCurrent Opinion in Genetics & Development, 2007
- Ba/F3 cells and their use in kinase drug discoveryCurrent Opinion in Oncology, 2007
- Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885Cancer Research, 2006
- Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastasesMolecular Cancer Therapeutics, 2006
- Mutations of the BRAF gene in human cancerNature, 2002
- Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase KinaseJournal of Biological Chemistry, 1998